1 / 7

Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars

China has an indispensable biosimilar market for overseas and multinational pharmaceutical companies. Historical data shows 40 per cent of China's $1.5bn recombinant biologic product sales come from biosimilars, which have enjoyed approximately 25-30 per cent CAGR over the past decade. If the market continues to grow at 25 per cent per year, the biosimilar market could grow to $2bn, around 20 per cent of the global biosimilar market by 2015. It is attracting more and more overseas and multinational pharmaceutical manufacturers and producers to penetrate such market.

AkshayKalla
Télécharger la présentation

Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars THE MARKET REPORTS Industry & Market Reports at its BEST.

  2. Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars Synopsis • Responding to strong desire of overseas and multinational pharmaceutical manufacturers and domestic pharmaceutical manufacturers to carry out research and development of biosimilar products, this is first time in history, Chinese pharmaceutical authorities, China Food and Drug Administration officially issued a technical guidance for development and evaluation of biosimilars and defined the pathway of license approval for biosimilars. Chinese pharmaceutical authorities require that when conducting the research and development of biosimilar products in China, the applicant of biosimilar registration application and its sponsor should be in compliance with the Guidance and follow the pathway of license approval of biosimilars. • How to grasp the opportunity to smoothly conduct the research and development of biosimilar products in China and speed up your biosimilar product approval time? The overseas and multinational pharmaceutical manufacturers and their senior executive officers engaging in regulatory affairs must have a comprehensive and thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of biosimilars. www.themarketreports.com

  3. Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars Key Drivers • Report Highlights • The applicable scope of Guidance. • An overview of general principles of development and evaluation of biosimilar products in China. • The detailed requirements for research and evaluation of pharmacy. • The detailed requirements for non-clinical research and evaluation. • The detailed requirements for clinical research and evaluation, from clinical pharmacology study covering pharmacokinetics study, pharmacodynamics study and (PK/PD) study, efficacy study, safety study, immunogenicity study to extrapolation of indications to smoothly navigate complex regulatory requirements step by step. • An overview of marketing license approval of biosimilars in China, from China’s registration category of biological products, specific pathway of license approval for imported biosimilar registration to application dossiers and data for license approval of biological products to guide you achieve a successful entry into the Chinese drug market, and smoothly operate your biosimilar products in China. • China’s Application Form of Drug Registration in English. www.themarketreports.com

  4. Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars Reasons To Buy China has an indispensable biosimilar market for overseas and multinational pharmaceutical companies. Historical data shows 40 per cent of China's $1.5bn recombinant biologic product sales come from biosimilars, which have enjoyed approximately 25-30 per cent CAGR over the past decade. If the market continues to grow at 25 per cent per year, the biosimilar market could grow to $2bn, around 20 per cent of the global biosimilar market by 2015. This is first time in history, Chinese pharmaceutical authorities, China Food and Drug Administration officially issued a technical guidance for development and evaluation of biosimilars and defined the pathway of license approval for biosimilars. Chinese pharmaceutical authorities require that when conducting the research and development of biosimilar products in China, the applicant of biosimilar registration application and its sponsor should be in compliance with the Guidance and follow the pathway of license approval of biosimilars. www.themarketreports.com

  5. Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars • The US generics market has been a massive growth driver for the India pharmaceutical market, with many leading companies in GMR Data’s list generating over 50% of their annual revenues from the US generics market. However with access to the US market comes increased scrutiny from the US FDA; nearly all the companies in the top ten have faced warnings from the FDA; ranging from minor procedural infractions to complete manufacturing shutdown. Purchase this report at https://www.themarketreports.com/report/buy-now/1256?license=Single_User_Price www.themarketreports.com

  6. Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars • Scope Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars provided a comprehensive and thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of biosimilars and guide you use the Chinese trial venues to keep biosimilars development lean and to smoothly operate in China. More information available at https://www.themarketreports.com/report/latest-chinese-guidance-for-development-evaluation-license-approval-of-biosimilars www.themarketreports.com

  7. How to REACH us: • Oh…that’s very simple, you can reach to us quickly via following medium: • Website: www.themarketreports.com • Email: sales@themarketreports.com • Call: +1-631-407-1315 • +91-750 729 14 79 • Skype: The Market Reports • We are looking forward to hear from you. www.themarketreports.com

More Related